149 related articles for article (PubMed ID: 2477560)
41. Radical prostatectomy as a monotherapy for locally advanced (stage T3) prostate cancer.
van den Ouden D; Davidson PJ; Hop W; Schröder FH
J Urol; 1994 Mar; 151(3):646-51. PubMed ID: 7508523
[TBL] [Abstract][Full Text] [Related]
42. Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group.
Teeter AE; Griffin K; Howard LE; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Freedland SJ
J Urol; 2018 Mar; 199(3):713-718. PubMed ID: 28870860
[TBL] [Abstract][Full Text] [Related]
43. Recurrent prostate cancer despite undetectable prostate specific antigen.
Takayama TK; Krieger JN; True LD; Lange PH
J Urol; 1992 Nov; 148(5):1541-2. PubMed ID: 1279216
[TBL] [Abstract][Full Text] [Related]
44. Selection of patients with stage B prostate cancer for radical prostatectomy.
Middleton RG; Larsen RH
Urol Clin North Am; 1990 Nov; 17(4):779-85. PubMed ID: 1699342
[TBL] [Abstract][Full Text] [Related]
45. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup.
Epstein JI; Carmichael M; Partin AW; Walsh PC
J Urol; 1993 Jun; 149(6):1478-81. PubMed ID: 8501792
[TBL] [Abstract][Full Text] [Related]
46. Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance.
Sengupta S; Christensen CM; Zincke H; Slezak JM; Leibovich BC; Bergstralh EJ; Myers RP; Blute ML
J Urol; 2006 Aug; 176(2):559-63. PubMed ID: 16813889
[TBL] [Abstract][Full Text] [Related]
47. The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer.
Carter HB; Partin AW; Epstein JI; Chan DW; Walsh PC
J Urol; 1990 Nov; 144(5):1167-70; discussion 1170-1. PubMed ID: 1700143
[TBL] [Abstract][Full Text] [Related]
48. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer.
Carver BS; Bianco FJ; Scardino PT; Eastham JA
J Urol; 2006 Aug; 176(2):564-8. PubMed ID: 16813890
[TBL] [Abstract][Full Text] [Related]
49. Effect of adjuvant radiation therapy on prostate specific antigen following radical prostatectomy.
Hudson MA; Catalona WJ
J Urol; 1990 Jun; 143(6):1174-7. PubMed ID: 1692887
[TBL] [Abstract][Full Text] [Related]
50. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.
Chaplin BJ; Wildhagen MF; Schroder FH; Kirkels WJ; Bangma CH
Eur Urol; 2005 Dec; 48(6):906-10. PubMed ID: 16126322
[TBL] [Abstract][Full Text] [Related]
51. MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy.
Silverman JM; Krebs TL
AJR Am J Roentgenol; 1997 Feb; 168(2):379-85. PubMed ID: 9016212
[TBL] [Abstract][Full Text] [Related]
52. [Progression after radical prostatectomy of cancer of the prostate: prognostic criteria and the role of PSA in monitoring].
Fendler JP; Dujardin T; Bringeon G; Adeleine P; Devonec M; Perrin P
Prog Urol; 1992 Feb; 2(1):58-65. PubMed ID: 1284386
[TBL] [Abstract][Full Text] [Related]
53. Characteristics of positive surgical margins in robotic-assisted radical prostatectomy, open retropubic radical prostatectomy, and laparoscopic radical prostatectomy: a comparative histopathologic study from a single academic center.
Albadine R; Hyndman ME; Chaux A; Jeong JY; Saab S; Tavora F; Epstein JI; Gonzalgo ML; Pavlovich CP; Netto GJ
Hum Pathol; 2012 Feb; 43(2):254-60. PubMed ID: 21820147
[TBL] [Abstract][Full Text] [Related]
54. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
[TBL] [Abstract][Full Text] [Related]
55. Needle biopsy of recurrent adenocarcinoma of the prostate after radical prostatectomy.
Ripple MG; Potter SR; Partin AW; Epstein JI
Mod Pathol; 2000 May; 13(5):521-7. PubMed ID: 10824923
[TBL] [Abstract][Full Text] [Related]
56. Prognostic Factors for Biochemical Recurrence More than 10 Years after Radical Prostatectomy.
Liesenfeld L; Kron M; Gschwend JE; Herkommer K
J Urol; 2017 Jan; 197(1):143-148. PubMed ID: 27418452
[TBL] [Abstract][Full Text] [Related]
57. Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy.
Gonzalez CM; Roehl KA; Antenor JV; Blunt LW; Han M; Catalona WJ
Urology; 2004 Oct; 64(4):723-8. PubMed ID: 15491709
[TBL] [Abstract][Full Text] [Related]
58. Re: Prostate specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation).
Fosså JD; Dearnaley DP
J Urol; 1992 Jan; 147(1):173-4. PubMed ID: 1370328
[No Abstract] [Full Text] [Related]
59. Long-term outcome of detectable PSA levels after radical prostatectomy.
Ahlering TE; Skarecky DW
Prostate Cancer Prostatic Dis; 2005; 8(2):163-6. PubMed ID: 15711604
[TBL] [Abstract][Full Text] [Related]
60. 25-Year disease-free survival rate after irradiation for prostate cancer calculated with the prostate specific antigen definition of recurrence used for radical prostatectomy.
Critz FA; Benton JB; Shrake P; Merlin ML
J Urol; 2013 Mar; 189(3):878-83. PubMed ID: 23103235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
